A Randomized Phase II/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in Gastric Carcinomatosis – STOPGAP II (EA2234) - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

A Randomized Phase II/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in Gastric Carcinomatosis – STOPGAP II (EA2234)

  • By

  • September 15, 2026

  • 1 min

Share

Objective:

To determine whether administering paclitaxel directly into the abdominal cavity in addition to chemotherapy given through a vein can lower the chance of gastric cancer growing or spreading and help patients live longer.

Approach:
  • Study population: People with gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, and peritoneal carcinomatosis.
  • Treatment being studied: Paclitaxel administered directly into the abdominal cavity in addition to chemotherapy given through a vein.
  • Comparison: The study compares this approach with the usual approach for gastric cancer.
Interpretation:

The study is evaluating whether adding paclitaxel administered directly into the abdominal cavity to chemotherapy given through a vein is better or worse than the usual approach for gastric cancer.

Limitations:
  • The provided context does not report trial results.
Sources:

Original Source(s)

Related Content